# Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

> **NCT02090127** · — · NO_LONGER_AVAILABLE · sponsor: **AVEO Pharmaceuticals, Inc.**

## Conditions studied

- Mullerian Mixed Tumor of Ovary

## Interventions

- **DRUG:** ficlatuzumab

## Key facts

- **NCT ID:** NCT02090127
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090127, "Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02090127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*